Literature DB >> 25589554

Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp).

Fredrik Barrenas1, Richard R Green2, Matthew J Thomas2, G Lynn Law2, Sean C Proll2, Flora Engelmann3, Ilhem Messaoudi4, Andrea Marzi5, Heinz Feldmann5, Michael G Katze6.   

Abstract

Vesicular stomatitis virus expressing Zaire Ebola virus (EBOV) glycoprotein (VSVΔG/EBOVgp) could be used as a vaccine to meet the 2014 Ebola virus outbreak. To characterize the host response to this vaccine, we used mRNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from cynomolgus macaques after VSVΔG/EBOVgp immunization and subsequent EBOV challenge. We found a controlled transcriptional response that transitioned to immune regulation as the EBOV was cleared. This observation supports the safety of the vaccine.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25589554      PMCID： PMC4340895          DOI： 10.1128/CVI.00733-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  14 in total

1.  Concomitant TLR/RLH signaling of radioresistant and radiosensitive cells is essential for protection against vesicular stomatitis virus infection.

Authors:  Julia Spanier; Stefan Lienenklaus; Jennifer Paijo; Annett Kessler; Katharina Borst; Sabrina Heindorf; Darren P Baker; Andrea Kröger; Siegfried Weiss; Claudia N Detje; Peter Staeheli; Ulrich Kalinke
Journal:  J Immunol       Date:  2014-08-15       Impact factor: 5.422

2.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Authors:  Daphne A Stanley; Anna N Honko; Clement Asiedu; John C Trefry; Annie W Lau-Kilby; Joshua C Johnson; Lisa Hensley; Virginia Ammendola; Adele Abbate; Fabiana Grazioli; Kathryn E Foulds; Cheng Cheng; Lingshu Wang; Mitzi M Donaldson; Stefano Colloca; Antonella Folgori; Mario Roederer; Gary J Nabel; John Mascola; Alfredo Nicosia; Riccardo Cortese; Richard A Koup; Nancy J Sullivan
Journal:  Nat Med       Date:  2014-09-07       Impact factor: 53.440

3.  Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.

Authors:  Maryam Ahmed; Latoya M Mitchell; Shelby Puckett; Kristina L Brzoza-Lewis; Douglas S Lyles; Elizabeth M Hiltbold
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

4.  Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Authors:  Thomas W Geisbert; Joan B Geisbert; Anders Leung; Kathleen M Daddario-DiCaprio; Lisa E Hensley; Allen Grolla; Heinz Feldmann
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

5.  TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages.

Authors:  Gernot Schabbauer; James Luyendyk; Karine Crozat; Zhengfan Jiang; Nigel Mackman; Siamak Bahram; Philippe Georgel
Journal:  Mol Immunol       Date:  2008-03-12       Impact factor: 4.407

6.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

7.  Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.

Authors:  Chad E Mire; Andrew D Miller; Angela Carville; Susan V Westmoreland; Joan B Geisbert; Keith G Mansfield; Heinz Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS Negl Trop Dis       Date:  2012-03-20

8.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

9.  Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.

Authors:  Xiangguo Qiu; Lisa Fernando; Judie B Alimonti; P Leno Melito; Friedericke Feldmann; Daryl Dick; Ute Ströher; Heinz Feldmann; Steven M Jones
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

10.  Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.

Authors:  Karen A O Martins; Jesse T Steffens; Sean A van Tongeren; Jay B Wells; Alison A Bergeron; Samuel P Dickson; John M Dye; Andres M Salazar; Sina Bavari
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240
View more
  10 in total

Review 1.  Interferon-stimulated genes: new platforms and computational approaches.

Authors:  Richard Green; Reneé C Ireton; Michael Gale
Journal:  Mamm Genome       Date:  2018-07-07       Impact factor: 3.224

2.  Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells.

Authors:  Martin Hölzer; Verena Krähling; Fabian Amman; Emanuel Barth; Stephan H Bernhart; Victor A O Carmelo; Maximilian Collatz; Gero Doose; Florian Eggenhofer; Jan Ewald; Jörg Fallmann; Lasse M Feldhahn; Markus Fricke; Juliane Gebauer; Andreas J Gruber; Franziska Hufsky; Henrike Indrischek; Sabina Kanton; Jörg Linde; Nelly Mostajo; Roman Ochsenreiter; Konstantin Riege; Lorena Rivarola-Duarte; Abdullah H Sahyoun; Sita J Saunders; Stefan E Seemann; Andrea Tanzer; Bertram Vogel; Stefanie Wehner; Michael T Wolfinger; Rolf Backofen; Jan Gorodkin; Ivo Grosse; Ivo Hofacker; Steve Hoffmann; Christoph Kaleta; Peter F Stadler; Stephan Becker; Manja Marz
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

3.  In vivo Ebola virus infection leads to a strong innate response in circulating immune cells.

Authors:  Ignacio S Caballero; Anna N Honko; Stephen K Gire; Sarah M Winnicki; Marta Melé; Chiara Gerhardinger; Aaron E Lin; John L Rinn; Pardis C Sabeti; Lisa E Hensley; John H Connor
Journal:  BMC Genomics       Date:  2016-09-05       Impact factor: 3.969

4.  Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.

Authors:  Xuan Liu; Emily Speranza; César Muñoz-Fontela; Sam Haldenby; Natasha Y Rickett; Isabel Garcia-Dorival; Yongxiang Fang; Yper Hall; Elsa-Gayle Zekeng; Anja Lüdtke; Dong Xia; Romy Kerber; Ralf Krumkamp; Sophie Duraffour; Daouda Sissoko; John Kenny; Nichola Rockliffe; E Diane Williamson; Thomas R Laws; Magassouba N'Faly; David A Matthews; Stephan Günther; Andrew R Cossins; Armand Sprecher; John H Connor; Miles W Carroll; Julian A Hiscox
Journal:  Genome Biol       Date:  2017-01-19       Impact factor: 13.583

Review 5.  Host Transcriptional Response to Ebola Virus Infection.

Authors:  Emily Speranza; John H Connor
Journal:  Vaccines (Basel)       Date:  2017-09-20

6.  Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation.

Authors:  Andrea Marzi; Andrea R Menicucci; Flora Engelmann; Julie Callison; Eva J Horne; Friederike Feldmann; Allen Jankeel; Heinz Feldmann; Ilhem Messaoudi
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

7.  Investigating the Cellular Transcriptomic Response Induced by the Makona Variant of Ebola Virus in Differentiated THP-1 Cells.

Authors:  Andrew Bosworth; Stuart D Dowall; Stuart Armstrong; Xuan Liu; Xiaofeng Dong; Christine B Bruce; Lisa F P Ng; Miles W Carroll; Roger Hewson; Julian A Hiscox
Journal:  Viruses       Date:  2019-11-04       Impact factor: 5.048

8.  Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease.

Authors:  Andrea Marzi; Allen Jankeel; Andrea R Menicucci; Julie Callison; Kyle L O'Donnell; Friederike Feldmann; Amanda N Pinski; Patrick W Hanley; Ilhem Messaoudi
Journal:  Front Immunol       Date:  2021-10-27       Impact factor: 7.561

9.  Comparison of Transcriptomic Platforms for Analysis of Whole Blood from Ebola-Infected Cynomolgus Macaques.

Authors:  Emily Speranza; Louis A Altamura; Kirsten Kulcsar; Sandra L Bixler; Cynthia A Rossi; Randal J Schoepp; Elyse Nagle; William Aguilar; Christina E Douglas; Korey L Delp; Timothy D Minogue; Gustavo Palacios; Arthur J Goff; John H Connor
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

10.  Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Authors:  Krista Versteeg; Andrea R Menicucci; Courtney Woolsey; Chad E Mire; Joan B Geisbert; Robert W Cross; Krystle N Agans; Daniel Jeske; Ilhem Messaoudi; Thomas W Geisbert
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.